Diabetic nephropathy in childhood and adolescents

Diabetes, Nutrition and Metabolism - Clinical and Experimental

Volumn 12, Issue 2, 1999, Pages 144-153

  Chiarelli, Francesco ^a,c   Casani, A ^a   Tumini, S ^a   Kordonouri, O ^b   Danne, T ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b HUMBOLDT UNIVERSITY   (Germany)

^c Policlinico   (Italy)

Author keywords

Adolescents; Children; Diabetic nephropathy; Type 1 diabetes mellitus

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; LISINOPRIL; LITHIUM ION; POLYOL; PROTEIN KINASE C; SODIUM ION; TRANSFORMING GROWTH FACTOR BETA;

ACUTE KIDNEY FAILURE; ADOLESCENT; BLOOD GLUCOSE MONITORING; CHILD; CLINICAL TRIAL; COUGHING; DIABETIC NEPHROPATHY; ENZYME ACTIVATION; GENE MUTATION; HEREDITY; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPOTENSION; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; MICROALBUMINURIA; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SMOKING CESSATION; SODIUM TRANSPORT; TERATOGENICITY;

ADOLESCENT; ADULT; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; GENETIC PREDISPOSITION TO DISEASE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; SMOKING;

EID: 0032821729     PISSN: 03943402     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Borch-Johnsen K., Andersen P.K., Deckert T.: The effect of proteinuria on relativity mortality in type 1 diabetes mellitus. Diabetologia 28: 590-596, 1985.
2. Bazzan M., Gruden G., Stella S., Vaccarino A., Tamponi G., Olivetti C., Giunti S., Cavallo-Perin P.: Microalbuminuria in IDDM is associated with increased expression of monocyte procoagulant activity. Diabetologia 91:2463-2469, 1998.
3. Dyer D.G., Dunn J.A., Thorpe S.R., Bailie K.E., Lyons T.J., McCance D.R., Baynes J.W.: Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J. Clin. Invest. 91: 2463-2469, 1993.
4. Makita Z., Radoff S., Rayfield E.J., Yang Z., Skolnik E., Delaney V., Friedman E.A., Cerami A., Vlassara H.: Advanced glycosylation end products in patients with diabetic nephropathy. N. Engl. J. Med. 325: 836-842, 1991.
5. Sell D.R., Lapolla A., Odetti P., Fogarty J., Monnier V.: Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes 41: 1286-1292, 1992.
6. McCance D.R., Dyer D.G., Dunn J.A., Bailie K.E., Thorpe S.R., Baynes J.W., Lyons T.J.: Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J. Clin. Invest. 91: 2470-2478, 1993.
7. Beisswenger P.J., Moore L.L., Brinck-Johnsen T., Curphey J.: Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy. J. Clin. Invest. 92: 212-217, 1993.
8. Beisswenger P.J., Makita Z., Curphey T.J., Moore L.L., Jean S., Brinck-Johnsen T., Bucala R., Vlassara H.: Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 44: 824-829, 1995.
9. Berg T.J., Dahl-Jorgensen K., Torjesen P.A., Hanssen K.F.: Increased serum levels of advanced glycation end products (AGEs) in children and adolescents with IDDM. Diabetes Care 20: 1006-1008, 1997.
10. Vlassara H.: Recent progress in advanced glycation end products and diabetic complications. Diabetes 46 (Suppl. 2): S19-S25, 1997.
11. Brownlee M., Cerami A., Vlassara H.: Advanced glycosylation end products in tissue and biochemical basis of diabetic complications. N. Engl. J. Med. 318: 1315-1321, 1988.
12. Doi T., Vlassara H., Kirstein M., Yamada Y., Striker G.E., Striker L.J.: Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc. Natl. Acad. Sci. USA 89: 2873-2877, 1992.
13. Yang G.W., Vlassara H., Peten E.P., He C-J., Striker G.E., Striker L.J.: Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc. Natl. Acad. Sci. USA 91: 9436-9440, 1994.
14. Vlassara H., Striker L.J., Teichberg S., Fuh H., Li X.M., Steffes M.: Advanced glycosylation end products induce glomerular sclerosis and albuminuria in normal rats. Proc. Natl. Acad. Sci. USA 91: 11704-11708, 1994.
15. Soulis-Liparota T., Cooper M., Papazoglou D., Clarke B., Jerums G.: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40: 1328-1334, 1991.
16. Cohen M.P.: Aldose reductase, glomerular metabolism and diabetic nephropathy. Metabolism 35: 55-59, 1986.
17. Goldfarb S., Ziyadeh F.N., Kern E.F.D., Simmons D.A.: Effects of polyol-pathway inhibition and dietary myoinositol on glomerular haemodynamic function in experimental diabetes mellitus in rats. Diabetes 40: 465-471, 1991.
18. Derylo B., Babazono T., Glogowski E., Kapor-Drezgic J., Hohman T., Whiteside C.: High glucose-induced mesangial cell altered contractility: role of the polyol pathway. Diabetologia 41: 507-515, 1998.
19. Ishii H., Tada H., Isogai S.: An aldose reductase inhibitor prevents glucose-induced increase in transforming growth factor β and protein kinase C activity in cultered human mesangial cells. Diabetologia 41: 362-364, 1998.
20. Koya D., King G.L.: Protein kinase C activation and the development of diabetic complications Diabetes 47: 859-866, 1998.
21. Haneda M., Araki S., Togawa M., Sugimoto T., Isono M., Kikkawa R.: Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultered under high glucose conditions. Diabetes 46: 847-853, 1997.
22. Koya D., Jirousek M.R., Lin Y.-W., Ishii H., Kuboki K., King G.L.: Characteristics of protein kinase C isoform activation on the gene expression of transforming growth factor β, extracellular matrix components and prostanoids in the glomeruli of diabetic rats. J. Clin. Invest. 100: 115-126, 1997.
23. Ishii H., Jirousek M.R., Koya D., Takagi C., Xia P., Clermont A., Bursell S.-E., Kern T.S., Ballas L.M., Heath W.F., Stramm L.E., Feener E.P., King G.L.: Amelioration of vascular disfunction in diabetic rats by an oral PKC inhibitor. Science 272: 728-731, 1996.
24. Baynes J.W.: Role of oxidative stress in development of complications in diabetes. Diabetes 40: 405-412, 1991.
25. Koya D, Lee I-K, Ishii H, Kanoh H, King GL. Prevention of glomerular dysfunction in diabetic rats by treatment of d-α-tocopherol. J. Am. Soc. Nephrol. 803: 426-435, 1997.
26. Krolewski A.S., Doria A., Magre J., Warram J.H., Housman D.: Molecular genetic approaches to the identification of genes involved in the development of nephropathy in insulin dependent diabetes mellitus. J. Am. Soc. Nephrol. 3: S9-S17, 1992.
27. Seaquist E.R., Goetz F.C., Rich S., Barbosa J.: Familial clustering of diabetic kidney disease. Evidence of genetic susceptibility to diabetic nephropathy. N. Engl. J. Med. 329: 1161-1165, 1989.
28. Quinn M., Angelico M.C., Warram J.H., Krolewski A.S.: Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 39: 940-945, 1996.
29. Mangili F., Bending J.J., Scott G., Li L.K., Gupta A., Viberti G.C.: Increased sodium lithium counter-transport activity in red cells of patients with insulin dependent diabetes and nephropathy. N. Engl. J. Med. 318: 146-150, 1988.
30. Jensen J.S., Mathiesen E.R., Norgaard K.: Raised blood pressure and red cell sodium lithium countertransport are not inherited in diabetic nephropathy. Diabetologia 33: 619-624, 1990.
31. Canessa M., Adragna N., Solomon H.S., Connolly T.M., Tosteson D.C.: Increased sodium lithium countertransport in red cells of patients with essential hypertension. N. Engl. J. Med. 302: 772-776, 1980.
32. Viberti G.C., Keen H., Wiseman M.J.: Raised arterial pressure in parents of proteinuric insulin dependent diabetics. B.M.J. 295: 515-517, 1985.
33. + countertransport measurement in essential hypertension, hyperlipidaemia and diabetic nephropathy: a critical review. Eur. J. Clin. Invest. 28: 339-352, 1998.
34. Monciotti C.G., Semplicini A., Morocutti A., Maioli M., Cipollina M.R., Barzon I., Palaro C., Brocco E., Trevisan M., Fioretto P., Crepaldi G., Nosadini R.: Elevated sodium-lithium countertransport activity in erythrocytes is predictive of the development of microalbuminuria in IDDM. Diabetologia 40: 654-661, 1997.
35. Brenner B.M., Chertow G.M.: Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury. Am. J. Kidney Dis. 23: 171-175, 1994.
36. Cambien F., Poirier O., Lecerf F., Evans A., Cambou J.P., Arveiler D., Luc G., Bard G.M., Bara Z., Ricard S.: Deletion polimorphism in the gene for angiotensin converting enzyme is associated with a parental hystory of myocardial infarction. Nature 359: 641-644, 1992.
37. Marre M., Bernadet P., Gallois Y., Savagner P., Guyen T.T., Hallab M., Cambien F., Passa P., Alhenc-Gelas F.: Relationship between angiotensin I converting enzyme gene polymorphism, plasma levels and diabetic retinal and renal complications. Diabetes 43: 384-388, 1994.
38. Tarnow L., Cambien F., Rossing P., Nielsen F.S., Hansen B.V., Lecerf L., Poirier O., Danilov S., Parving H.H.: Lack of relationship between an insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 44: 489-494, 1995.
39. Schmidt S., Schone N., Ritz E., The Diabetic Nephropathy Study Group: Association of ACE gene polymorphism and diabetic nephropathy? Kidney Int. 47: 1176-1181, 1995.
40. Ringel J., Beige J., Kunz R., Distler A., Sharma A.M.: Genetic variants of the renin-angiotensin system, diabetic nephropathy and hypertension. Diabetologia 40: 193-199, 1997.
41. Barnas U., Schmidt A., Illievich A., Kiener H.A., Rabensteiner D., Kaider A., Prager R., Abrahamian H., Irsigler K., Mayer G.: Evaluation of risk factor for the development of nephropathy in patients with IDDM: insertion/deletion angiotensin converting enzyme gene polymorphism hypertension and metabolic control. Diabetologia 40: 327-333, 1997.
42. Miller J.A., Scholey J.W., Thai K., Pei Y.P.C.: Angiotensin converting enzyme gene polymorphism and renal haemodynamic function in early diabetes. Kidney Int. 51: 119-124, 1997.
43. Marre M., Jeunemaitre X., Gallois Y., Rodier M., Chatellier G., Sert C., Dusselier L., Kahal Z., Chaillous L., Halimi S., Muller A., Sackmann H., Bauduceau B., Bled F., Passa P., Alhenc-Gelas F.: Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin dependent diabetes. J. Clin. Invest. 99: 1585-1595, 1997.
44. Fujisawa T., Ikegami H., Kawaguchi Y., Hamada Y., Veda H., Shintani M., Fukuda M., Ogihara T.: Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 41: 47-53, 1998.
45. Doria A., Warram J.H., Krolewski A.S.: Genetic predisposition to diabetic nephropathy: evidence for a role of the angiotensin I-converting enzyme gene. Diabetes 43: 690-695, 1994.
46. Chowdhury T.A., Dyer P.H., Kumar S., Gough S.C.L., Gibson S.P., Rowe B.R., Smith P.R., Dronsfield M.J., Marshall S.M., Mackin P., Dean J.D.. Morris P.J., Davies S., Dunger D.B., Boulton A.J.M., Barnett A.H., Bain S.C.: Lack of association of angiotensin II receptor gene polymorphism with diabetic nephropathy in insulin-dependent diabetes mellitus. Diabet. Med. 14: 837-840, 1997.
47. Doria A., Onuma T., Warram J.H., Krolewski A.S.: Synergistic effect of angiotensin II type 1 receptor genotype and poor glycaemic control on risk of nephropathy in IDDM. Diabetologia 40: 1293-1299, 1997.
48. Doria A., Onuma T., Gearin G., Freire M.B.S., Warram J.H., Krolewski A.S.: Angiotensin polymorphism M235+, hypertension and nephropathy in insulin-dependent diabetes. Hypertension 27: 1134-1139, 1996.
49. Tarnow L., Cambien F., Rossing P., Nielsen F.S., Hansen B.V., Ricard S., Poirier O., Parving H.H.: Angiotensinogen gene polymorphisms in IDDM patients with diabetic nephropathy. Diabetes 45: 367-369, 1996.
50. Fogarty D.G., Harron J.C., Hughes A.E., Nevin N.C., Doherty C.C., Maxwell A.P.: A molecular variant of angiotensinogen is associated with diabetic nephropathy in IDDM. Diabetes 45: 1204-1208, 1996.
51. Jeunemaitre X., Soubrier P., Kotelevtsev Y.V., Lifton R.P., Williams C.S., Charru A., Hunt S.C., Hopkins P.N., Williams R.R., Lalouel J.M., Corvol P.: Molecular basis of human hypertension. Role of angiotensinogen. Cell 71: 169-180, 1992.
52. Heesom A.E., Hibberd M.L., Millward A., Demaine A.G.: Plymorphysm in the 5'-end of the aldose reductase gene is strongly associated with the develpment of diabetic nephropathy in type 1 diabetes. Diabetes 46: 287-291, 1997.
53. Parving H.H., Jacobsen P., Tarnow L., Rossing P., Lecerf L., Poirier O., Cambien F.: Effect of deletion polymorphism of angiotensin enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme:observational follow up study. B.M.J. 591-594, 1996.
54. Bojestig M., Arnqvist H.J., Hermansson G., Karlberg B.E., Ludvigsson J.: Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N. Engl. J. Med. 330: 15-18, 1994.
55. Balodimos M.C., Legg M.A., Bradley R.F.: Diabetic glomerulosclerosis in children. Diabetes 20: 622-625, 1971.
56. Rudberg S., Osterby R., Dahlquist G., Nyberg G., Persson B.: Predictors of renal morphological changes in the early stage of microalbuminuria in adolescents with IDDM. Diabetes Care 20: 265-271, 1997.
57. Silverstein J.H., Fenell R., Donelly W., Banks R., Stratton R., Spillar R., Rosenbloom A.L.: Correlates of biopsy-studied nephropathy in young patients with insulin dependent diabetes mellitus. J. Pediatr. 106: 196-201, 1985.
58. Bangstad H.J., Osterby R., Dahl-Jorgensen K., Berg K.J., Hartmann A., Nyberg G., Frahm-Bjorn S., Hansen K.F.: Early glomerulopathy is present in young, type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 36: 523-529, 1993.
59. Rudberg S., Persson B.: Association between lipoprotein (a) and insulin-like growth factor-1 during puberty and the relationship to microalbuminuria in children and adolescents with IDDM. Diabetes Care 18: 933-939, 1995.
60. Rudberg S., Persson B.: Indications of low sex hormone binding globulin (SHBG) in young females with type 1 diabetes and an independent association to microalbuminuria. Diabet. Med. 12: 816-822, 1995.
61. Lawson M.L., Sochett E.B., Chait P.G., Balfe J.W., Daneman D.: Effect of puberty on markers of glomerular hypertrophy and hypertension in IDDM. Diabetes 45: 51 -55, 1996.
62. Cummings E.A., Sochett E.B., Dekker M.G., Lawson M.L., Daneman D.: Contribution of growth hormone and IGF-1 to early diabetic nephropathy in type 1 diabetes. Diabetes 47: 1341-1346, 1998.
63. Barkai L., Vamosi I., Lukacs K.: Enhanced progression of urinary albumin excretion in IDDM during puberty. Diabetes Care 21: 1019-1023, 1998.
64. Kostraba J.N., Dorman J.S., Orchard T.J., Becker D.J., Ohki Y., Ellis D., Doft B.H., Lobes L.A., LaPorte R.E., Drash A.L.: Contribution of diabetes duration before puberty to development of microvascular complications in IDDM subjects. Diabetes Care 12: 686-699, 1989.
65. Williamson J.R., Rowold E., Chang K., Marvel J., Tomilison M., Sherman W.R., Ackermann K.E., Berger R.A., Kilo C.: Sex steroid dependency of diabetes induced changes in polyol metabolism, vascular permeability and collagen cross linking. Diabetes 35:20-27, 1986.
66. Mortensen H.B., Robertson K.J., Aanstoot H.-J., Danne T., Holl R.W., Hougaard P., Atchinson J.A., Chiarelli F., Daneman D., Dinesen B., Dorchy H., Garandeau P., Greene S., Hoey H., Kaprio E.A., Kocova M., Martul P., Matsuura N., Schoenle E.J., Søvik O., Swift P.G.F., Tsou R.M., Vanelli M., Åman J., for The Hvidøre Study Group on Childhood Diabetes: Insulin management and metabolic control of Type 1 diabetes mellitus in childhood and adolescence in 18 countries. Diabet. Med. 15: 752-759, 1998.
67. Borch-Johnsen K., Wenzel H., Viberti G.C., Mogensen C.E.: Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes? Br. Med. J. 306: 1722-1725, 1993.
68. Mogensen C.E., Vestbo E., Logstrup Poulsen P., Christiansen C., Damsgaard E.M., Eiskjaer H., Froland A., Hansen K.W., Nielsen S., Pedersen M.M.: Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care 18: 572-581, 1995.
69. Poulsen P.L., Mogensen C.E.: Clinical evaluation of a test for immediate and quantitative determination of urinary albumin-to-creatinine ratio. Diabetes Care 21: 97-98, 1998.
70. Mortensen H.B., Hougaard P., Ibsen K.K., Parving H.H;, Marinelli K., Norgaard K., Main K., Kastrup K.W., Ibsen K.K.: A nation-wide cross-sectional study of urinary albumin excretion rate, arterial blood pressure and blood glucose control in Danish children with Type 1 diabetes. Diabet. Med. 7: 887-897, 1990.
71. Joner G, Brinchmann-Hansen O., Torres C.G., Hanssen K.F.: A nationwide cross-sectional study of retinopathy and microalbuminuria in young Norwegian type I (insulin-dependent) diabetic patients. Diabetologia 35: 1049-1054, 1992.
72. Danne T., Kordonouri O., Hövener G., Weber B.: Diabetic angiopathy in children. Diabet. Med. 14: 1012-1025, 1997.
73. Mortensen H.B.: Microalbuminuria in young patients with type 1 diabetes. In: Mogensen C.E., (Ed.), The kidney and hypertension in diabetes mellitus, ed. 3. Kluwer Academic Publ., Boston-London, 1996, pp. 331-340.
74. Mathiesen E.R., Saurbrey N., Hommel E., Parving H.H.: Prevalence of microalbuminuria in children with Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 29: 640-643, 1986.
75. Dahlquist G., Rudberg S.: The prevalence of microalbuminuria in diabetic children and adolescents and its relation to puberty. Acta Pediatr. Scand. 76: 795-800, 1987.
76. Janner M., Knill S.E., Diem P., Zuppinger K.A., Mullis P.E.: Persistent microalbumniuria in adolescents with type I (insulin-dependent) diabetes mellitus is associated to early rather than late puberty. Results of a prospective longitudinal study. Eur. J. Ped. 153: 403-408, 1994.
77. Jones C.A., Leese G.P., Kerr S., Bestwick K., Isherwood D.I., Vora J.P., Hughes D.A., Smith C. Development and progression of microalbuminuria in a clinic sample of patients with insulin dependent diabetes mellitus. Arch. Dis. Child. 78: 518-523, 1998.
78. Shield J.P., Hunt L.P., Karachaliou F., Karavanaki K., Baum J.D.: Is microalbuminuria progressive? Arch. Dis. Child. 73: 512-514, 1995.
79. Orchard T.J., Dorman J.S., Maser R.E., Becker D.J., Drash A.L., Ellis D., LaPorte R.E., Kuller L.H.: Prevalence of complications in IDDM by sex and duration. Pittsburgh epidemiology of diabetes complications study II. Diabetes 39: 1116-1124, 1990.
80. Bojestig M., Arnquist H.J., Karlberg B.E., Ludvigsson J.: Glycemic control and prognosis in type I diabetic patients with microalbuminuria. Diabetes Care 19: 313-317, 1996.
81. Mathiesen E.R., Feldt-Rasmussen B., Hommel E., Decken T., Parving H.H.: Stable glomerular filtration rate in normotensive IDDM patients with stable microalbuminuria. Diabetes Care 20: 286-289, 1997.
82. Rudberg S., Dahlquist G.: Determinants of progression to microalbuminuria in adolescents with IDDM. Diabetes Care 19: 369-371, 1996.
83. Rudberg S., Ullman E., Dahlqiust G.: Relationship between early metabolic control and the development of microalbuminuria-a longitudinal study in children with type 1 (insulin-dependent) diabetes. Diabetologia 36: 1309-1314, 1993.
84. Stephenson J.M., Fuller J.H., EURODIAB IDDM: Microalbuminuria is not rare before 5 years of IDDM. J. Diab., Comp. 8: 166-173, 1994.
85. Mullis P., Köchli H.P., Zuppinger K., Schwarz H.P.: Intermittent microalbuminuria in children with type 1 diabetes mellitus without clinical evidence of nephropathy. Eur. J. Pediatr. 147: 385-388, 1988.
86. Danne T., Kordonouri O.: Controversis in the pathogenesis of diabetic angiopathy: which treatment for normotensive adolescents with microalbuminuria and type 1 diabetes. J. Pediatr. Endocrinol. Metab. 11 (Suppl. 2): 347-363, 1998.
87. The Diabetes Control and Complications Study Group.: Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus. J. Fed. 125: 177-188, 1994.
88. Bangstad H.J., Osterby R., Dahl-Jorgensen K., Berg K.J., Hartmann A., Hanssen K.F.: Improvement of blood glucose control retards the progression of morphological changes in early diabetic nephropathy. Diabetologia 37: 483-490, 1994.
89. Mogensen C.E.: Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br. Med. J. 285: 685-688, 1982.
90. Mathiesen E.R., Hommel E., Giese J., Parving H.H.: Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. Br. Med. J. 303: 81-87, 1991.
91. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. for the Collaborative Study Group: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 329: 1456-1462, 1993.
92. The Microalbuminuria Captopril Study Group: Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 39: 587-593, 1996.
93. Cook J., Daneman D., Spino M., Sochett E., Perlman K., Balfe J.W.: Angiotensin converting enzyme inhibitor therapy to decrease microlbuminuria in normotensive children with insulin-dependent diabetes mellitus. J. Ped. 117: 39-45, 1990.
94. Rudberg S., Aperia A., Freyschuss U., Persson B.: Enalapril reduces microalbuminuria in young normotensive Type 1 (insulin-dependent) diabetic patients irrespective of its hypotensive effect. Diabetologia 33: 470-476, 1990.
95. Hostetter T.H.: Patogenesis of diabetic glomerulopathy: haemodynamic considerations. Semin. Nephrol. 10: 219-227, 1990.
96. Egido J.: Vasoactive hormones and renal sclerosis. Kidney Int. 49: 578-597, 1996.
97. Mogensen C.E., Keane W.F., Bennett P.H., Jerums G., Parving H.H., Passa P., Steffes M.W., Striker G.E., Viberli G.C.: Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346: 1080-1084, 1995.
98. The EUCLID Study Group: Randomised placebo-controlled trial of lisinopril in normotesive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 349: 1787-1792, 1997.
99. Almdal T., Norgaard K., Feldt-Rasmussen B., Decken T.: The predictive value of microalbuminuria in IDDM. Diabetes Care 17: 120-125, 1994.
100. Teochari M.A., Vyssoulis G.P., Toutouzas P.K., Bartsocas C.S.: Arterial blood pressure changes in children and adolescents with insulin-dependent diabetes mellitus. J. Ped. 129: 667-670, 1996.
101. Madacsy L., Yasar A., Tulassay T., K̂rner A., Kelemen J., Hobor M., Miltenyi: Relative nocturnal hypertension in children with insulin-dependent diabetes mellitus. Acta Paediatr. 83: 414-17, 1994.
102. Poulsen P.L., Hansen K.W., Mogensen C.E.: Ambulatory blood pressure in the transition from normo-to microalbuminuria, a longitudinal study in IDDM patients. Diabetes 43: 1248-1253, 1995.
103. Virdis R., Vanelli M., Street M., Zampolli M.. De Fanti A., Cantoni S., Vittorangeli F., Pezzarossa A., Giovanelli G., Terzi C.: Blood pressure tracking in adolescents with insulin-dependent diabetes mellitus. J Hum. Hypertension 8: 313-317, 1994.
104. Fioretto P., Steffes M.W., Sutherland D.E.R., Mauer M.: Sequential biopsies in insulin-dependent diabetic patients structural factors associated with clinic progression. Kidney Int. 48: 1929-1935, 1995.
105. Bangstad H.J., Osterby R., Hartmann A., Berg T.J., Dahl-Jorgensen K., Hanssen K.F.: Renal morphological changes predict urinary albumin excretion rate 6 years later in patients with IDDM and microalbuminuria. Diabetologia 4 (Suppl. 1): A 530, 1997.
106. Anderson J., Rocchini A.P.: Hypertension in individuals with insulin-dependent diabetes mellitus. Pediat. Clin. North Amer. 40: 93-104, 1993.
107. Mirkin B.L., Newman T.J.: Efficacy and safety of captopril in the treatment of severe childhood hypertension: report of the International Collaborative Study Group. Pediatrics 75: 1091-1100, 1985.
108. Norgaard K., Storm B., Grae M., Feldt-Rasmussen B.: Elevated albumin excretion and retinal changes in children with type I diabetes are related to long-term poor blood glucose control. Diabet. Med. 6: 325-328, 1989.